This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LabCorp (LH) Q2 Earnings Surpass Estimates, 2021 View Raised
by Zacks Equity Research
LabCorp (LH) Diagnostics revenues in the second quarter increase significantly on organic Base Business volume improvements despite decelerating demand for COVID-19 testing.
West Pharmaceutical (WST) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strong segmental performance.
Hologic's (HOLX) Q3 Earnings Top Estimates, Q4 View Dull
by Zacks Equity Research
Impressive performance by the Breast Health and GYN Surgical segments drive Hologic's (HOLX) fiscal third-quarter revenues.
Align Technology (ALGN) Q2 Earnings Top Estimates, 2021 View Up
by Zacks Equity Research
Strength in Invisalign Clear Aligners and iTero scanners sales volumes during the fiscal second quarter drove Align Technology's (ALGN) top line.
West Pharmaceutical Services (WST) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
West Pharmaceutical (WST) delivered earnings and revenue surprises of 41.38% and 8.72%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Masimo's (MASI) Q2 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong rebound in sensor sales, drive its Q2 sales.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect strong performance across Orthopaedics, MedSurg and Neurotechnology and Spine segments.
What's in Store for West Pharmaceutical's (WST) Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Cardinal Health (CAH) Introduces 2 New Digital Solutions
by Zacks Equity Research
Cardinal Health (CAH) launches NavixRx Compliance Packaging and E-Commerce Storefront to allow independent pharmacists to expand services and support medication adherence.
West Pharmaceutical Services (WST) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
West Pharmaceutical (WST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Stocks to Tap the Promising Dental Supplies Industry
by Trina Mukherjee
Despite the COVID-19 pandemic induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical-Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.
What Makes Align Technology (ALGN) a Solid Choice Right Now?
by Zacks Equity Research
Strong performance and latest innovations in the Invisalign and iTero family are driving the top line for Align Technology (ALGN).
Grab these 3 MedTech Stocks That Outperformed S&P 500 YTD
by Trina Mukherjee
Snap up these three top stocks, WST, PAHC and RMD, which continue to show promise amid the pandemic and can turn out to be prudent investment choices.
West Pharmaceutical (WST) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about West Pharmaceutical's (WST) solid proprietary products segment.
Bet on 4 Low-Beta MedTech Stocks to Ride the Choppy Market
by Riya Anand
Stocks like Henry Schein (HSIC), BellRing Brands (BRBR), Harrow Health (HROW) and West Pharmaceuticals Services (WST) are solid low-beta picks with strong fundamentals.
3 Best MedTech Growth Stocks to Bet On in 2021 Amid Pandemic
by Trina Mukherjee
Grab these three top stocks, EYE, WST and HSIC, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.
Reasons to Add West Pharmaceutical (WST) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about West Pharmaceutical (WST) due to its solid proprietary products segment.
Align (ALGN) to Launch Limited-Edition Invisalign Aligner Case
by Zacks Equity Research
Align (ALGN) partners with a popular social media star to release a limited-edition case for Invisalign aligners.
Patterson Companies (PDCO) Q4 Earnings Miss, Revenues Beat
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter 2021 results benefit from strong segmental performance.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at Dental segment.
BD's (BDX) Rapid COVID-19 Test for US Olympic Trial Swimmers
by Zacks Equity Research
BD (BDX) to provide rapid antigen testing for COVID-19 at the U.S. Olympic Team Trials and other competitive swimming events on behalf of USA Swimming.
Walgreens (WBA) Rolls Out Plan to Boost COVID-19 Vaccination
by Zacks Equity Research
Walgreens Boots' (WBA) U.S. pharmacy segment to extend pharmacy timings for COVID-19 vaccination in support of Biden administration's vaccination efforts.
Is West Pharmaceutical (WST) a Great Growth Stock?
by Zacks Equity Research
If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider West Pharmaceutical (WST).
Align Technology (ALGN) Launches New Features in iTero Family
by Zacks Equity Research
Align Technology's (ALGN) iTero Workflow 2.0 software and iTero Element 5D Imaging system auto-upload functionality to drive innovation in digital orthodontics and restorative dentistry.
Zimmer Biomet (ZBH) Witnesses Post-Pandemic Business Revival
by Zacks Equity Research
Zimmer Biomet's (ZBH) spin-off decision of the non-core dental and spine business is expected to prove strategic.